DEF 14A: Agilon Health Files Definitive Proxy Statement for 2024 Annual Meeting

Agilon Health has released its definitive proxy statement, outlining proposals for the upcoming annual meeting of stockholders scheduled for May 29, 2024.

Summary

• Agilon Health has filed a definitive proxy statement for its 2024 Annual Meeting of Stockholders, which will be held virtually on May 29, 2024.
• Stockholders will vote on the election of three Class III directors, ratification of Ernst & Young LLP as the company's independent registered public accounting firm, and an advisory vote on executive compensation.
• The board recommends voting FOR the election of the director nominees and FOR the ratification of Ernst & Young LLP and the advisory vote on executive compensation.
• The company's mission is to be the trusted long-term partner of community-based physicians, enabling them to reimagine the patient experience for older adults and lead the transformation of care delivery in their communities.
• Agilon's Total Care Model aims to shift PCPs from volume to value, leading to better care for seniors and better cost care, with more than $200 million reinvested back into local primary care last year.
• The company has 31 partners in 13 states, representing over 2,400 PCPs in 30+ communities and around 650,000 senior patients.
• The Compensation and Human Capital Committee reduced the overall company score, and annual incentive compensation pool payout funding, to 50% of the target due to missing the 2023 Adjusted EBITDA threshold and overall Company performance falling short of expectations.
• The committee also determined that the Chief Executive Officer, and other NEOs, as well as certain other executives who report to the Chief Executive Officer, would receive a 0% payout for the annual incentive program.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While it highlights the company's mission, growth, and positive aspects of its care model, it also acknowledges industry challenges, missed financial targets, and executive compensation adjustments. The forward-looking statements are cautiously optimistic.

Positives

• Agilon Health's Total Care Model is helping PCPs shift from volume to value, leading to better care for seniors and better cost care.
• The company has made considerable reinvestments back into local primary care, reinvesting more than $200 million last year.
• Agilon Health has 31 partners in 13 states, representing over 2,400 PCPs and around 650,000 senior patients.
• The company's Physician Network continues to drive quality outcomes, including quality scores at four and above.
• Demand for the agilon platform has never been stronger.

Negatives

• The Compensation and Human Capital Committee reduced the overall company score, and annual incentive compensation pool payout funding, to 50% of the target due to missing the 2023 Adjusted EBITDA threshold and overall Company performance falling short of expectations.
• The committee also determined that the Chief Executive Officer, and other NEOs, as well as certain other executives who report to the Chief Executive Officer, would receive a 0% payout for the annual incentive program.

Risks

• The document mentions several risks that could cause actual results to differ materially from forward-looking statements, including the company's history of net losses, failure to identify and develop successful new partnerships, medical expenses exceeding revenues, and the impact of changes to federal government healthcare programs.
• The company is navigating through a complex transition period for the industry due to external challenges, as costs among the senior population rose faster than contemplated in Centers for Medicare & Medicaid Services (CMS) benchmarks and payor bids due to increased utilization.

Future Outlook

The company believes that agilon and the broader industry will adjust to the new environment of higher utilization among the senior population, supporting the ability to return to a more normalized margin trajectory over time.

Management Comments

• 'As we make progress toward our actions, it's important to remember that our business model is working. In fact, demand for our platform has never been stronger, and our Physician Network continues to drive quality outcomes, including quality scores at four and above,' stated Steve Sell, CEO.
• Steve Sell, CEO, noted that the company's full-risk Total Care Model is helping PCPs make the shift from volume to value, leading to better care for seniors and better cost care.

Industry Context

The document notes that the Medicare Advantage sector is navigating a complex transition period due to rising costs among the senior population and increased utilization.

Comparison to Industry Standards

• The peer group used for executive compensation benchmarking includes companies like Alignment Healthcare, Cano Health, Evolent Health, Oak Street Health, and Teladoc Health, representing similar business dynamics and competition for talent.
• The company's ESG reporting is informed by the Sustainability Accounting Standards Board (SASB) framework.

Management Changes

Corporate Governance

Related Party Transactions

• On May 15, 2023, the Company, the CD&R Investor and certain other selling stockholders (collectively, the Selling Stockholders) and J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and BofA Securities, Inc., as representatives of the several underwriters named therein (collectively, the Underwriters) entered into an Underwriting Agreement (the Underwriting Agreement), pursuant to which the Selling Stockholders agreed to sell to the Underwriters, and the Underwriters agreed to purchase from the Selling Stockholders, subject to and upon the terms and conditions set forth therein, 86,884,353 shares of our common stock.
• The CD&R Investor also granted the Underwriters a 30-day option to purchase up to an additional 7,726,955 shares of common stock, which option was exercised in full on May 16, 2023.
• The Company also agreed, subject to the completion of the offering, to purchase 9,614,806 shares of the common stock sold to the Underwriters at the same per share price paid by the Underwriters to the Selling Stockholders in the offering.
• During the year ended December 31, 2023, the Company recognized general and administrative expenses of $1.7 million to administer this secondary offering of shares of its common stock sold by the Selling Stockholders and did not receive any proceeds from any sale of common stock.

Stakeholder Impact

• The company's actions aim to ensure physician partners thrive alongside their patients.
• The Total Care Model focuses on improving patient outcomes and experience for seniors.
• The company strives to leverage its employees and resources to support communities through efforts to address Social Determinants of health and conditions that impact senior patients.

Next Steps

• Stockholders are encouraged to review the proxy materials and vote on the proposals.
• The company will release its third Impact Report prior to the Annual Meeting.
• The company plans to develop an inventory of its Scopes 1 and 2 emissions for baseline year 2023.

Key Dates

Keywords

proxy statement, annual meeting, directors, executive compensation, agilon health, stockholders, governance, healthcare, physicians, value-based care